Prothena (PRTA) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prothena (PRTA) has outperformed Rezolute (RZLT) over the past year, losing 16.6% versus a loss of 46.8%. Over five years, RZLT leads with a -30.2% price change compared with -86.6% for PRTA. Rezolute is the larger company by market cap ($448.8 million vs $442.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRTA | RZLT |
|---|---|---|
| Share price | $8.61 | $4.64 |
| Market cap | $442.01M | $448.79M |
| 1-day change | +1.53% | +5.94% |
| YTD return | -11.20% | +96.61% |
| 1-year return | -16.62% | -46.79% |
| 5-year return | -86.64% | -30.23% |
| EPS (TTM) | $-0.82 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.80 | $11.46 |
| 52-week low | $7.73 | $1.07 |
| Distance from 52-week high | -27.03% | -59.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +148.55% | +111.21% |
| Average volume | 484.51K | 1.50M |
| Shares outstanding | 51.34M | 96.72M |
| Employees | 67 | 58 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRTA has outperformed RZLT by 30.2 percentage points over the past year.
- The two companies sit in different sectors: Prothena in Health Care and Rezolute in Healthcare.
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Healthcare · Biotechnology · 58 employees
PRTA vs RZLT FAQ
Which is bigger, Prothena or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $448.79M compared with $442.01M for Prothena (PRTA).
Which stock has performed better over the past year, PRTA or RZLT?
PRTA returned -16.62% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Prothena and Rezolute in the same industry?
No. Prothena is in the Health Care sector, while Rezolute is in Healthcare.